Metabolomic profile in TB
The aim of this study is to characterize the specific urinary metabolome released from TB patients by nuclear magnetic resonance in order to be used for diagnostic purposes.
Performance of a new generation IGRA in immunocompromised individuals
This study is designed to evaluate the performance of this new ELISA based QuantiFERON-TB plus In-tube test in immunosuppressed populations.
Migrant-sensitive care and tuberculosis treatment outcome and completion
The aim of the study is to assess whether migrant-sensitive care strategies lead to an increase of successful active TB and LTBI treatment outcomes in migrants.
Berit Lange & Heinke Kunst
A prospective descriptive cross-sectional observational study
Tuberculosis Screening in Ukrainian Refugees: Countries practices
Raquel Duarte, Mariana Conde
Management of tuberculosis in transplant recipients
This multicentric retrospective cohort study will compare the incidence of tuberculosis at least two years after transplant in those with screening and those without screening.
Clinical Evaluation of mfloDx™ test kit
This study aims to assess the clinical impact of the miniMDR-TB test for the diagnosis of multidrug-resistant tuberculosis.
Sven Hoffner, Jose Dominguez
Pragmatic trial on safety and tolerability of an optimized (high) dose of rifampicin in tuberculosis patients’
Rifampicin Trial (PORT)
Xpert MTB/RIF false positive results in patients with tuberculosis
risk factors and impact on clinical outcome
Validation of a health care index for short term mortality for tuberculosis (TB) among People Living with HIV
We hypothesize that a Health Care Index (HCI) derived from a European TB/HIV co-infection cohort does equally predict the probability for death in other cohorts from various settings.
Management of XDR-TB in Europe
This study will aim to describe the clinical management of XDR-TB in Europe according to the revised definition, and retrospectively evaluate its treatment outcomes.
Yousra Kherabi, Lorenzo Guglielmetti
Use of hepatoprotective drugs during anti-tuberculosis treatment
We wish to evaluate and map the prevalence of use of “hepatoprotective drugs” for patients who receive antituberculosis treatments in different countries of the WHO Europe Region.